242 related articles for article (PubMed ID: 18955520)
21. Antiviral treatment and prophylaxis of influenza in primary care: German recommendations.
Wutzler P; Kossow KD; Lode H; Ruf BR; Scholz H; Vogel GE;
J Clin Virol; 2004 Oct; 31(2):84-91. PubMed ID: 15364262
[TBL] [Abstract][Full Text] [Related]
22. [Neuraminidase inhibitor, anti-influenzal agent--mechanism of action, and how to use clinically].
Kaji M
Nihon Rinsho; 2003 Nov; 61(11):1975-9. PubMed ID: 14619441
[TBL] [Abstract][Full Text] [Related]
23. Neuraminidase inhibitor R-125489--a promising drug for treating influenza virus: steered molecular dynamics approach.
Mai BK; Li MS
Biochem Biophys Res Commun; 2011 Jul; 410(3):688-91. PubMed ID: 21693105
[TBL] [Abstract][Full Text] [Related]
24. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
Ferraris O; Kessler N; Lina B
Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats.
Koyama K; Takahashi M; Nakai N; Takakusa H; Murai T; Hoshi M; Yamamura N; Kobayashi N; Okazaki O
Xenobiotica; 2010 Mar; 40(3):207-16. PubMed ID: 20146556
[TBL] [Abstract][Full Text] [Related]
26. Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses.
Hsu PH; Chiu DC; Wu KL; Lee PS; Jan JT; Cheng YE; Tsai KC; Cheng TJ; Fang JM
Eur J Med Chem; 2018 Jun; 154():314-323. PubMed ID: 29843102
[TBL] [Abstract][Full Text] [Related]
27. Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza.
Macdonald SJ; Cameron R; Demaine DA; Fenton RJ; Foster G; Gower D; Hamblin JN; Hamilton S; Hart GJ; Hill AP; Inglis GG; Jin B; Jones HT; McConnell DB; McKimm-Breschkin J; Mills G; Nguyen V; Owens IJ; Parry N; Shanahan SE; Smith D; Watson KG; Wu WY; Tucker SP
J Med Chem; 2005 Apr; 48(8):2964-71. PubMed ID: 15828835
[TBL] [Abstract][Full Text] [Related]
28. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.
Zürcher T; Yates PJ; Daly J; Sahasrabudhe A; Walters M; Dash L; Tisdale M; McKimm-Breschkin JL
J Antimicrob Chemother; 2006 Oct; 58(4):723-32. PubMed ID: 16891631
[TBL] [Abstract][Full Text] [Related]
29. [Neuraminidase inhibitor].
Kaji M
Nihon Rinsho; 2000 Nov; 58(11):2293-8. PubMed ID: 11225320
[TBL] [Abstract][Full Text] [Related]
30. Correlation analyses on binding affinity of sialic acid analogues and anti-influenza drugs with human neuraminidase using ab initio MO calculations on their complex structures--LERE-QSAR analysis (IV).
Hitaoka S; Matoba H; Harada M; Yoshida T; Tsuji D; Hirokawa T; Itoh K; Chuman H
J Chem Inf Model; 2011 Oct; 51(10):2706-16. PubMed ID: 21870866
[TBL] [Abstract][Full Text] [Related]
31. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors.
Escuret V; Frobert E; Bouscambert-Duchamp M; Sabatier M; Grog I; Valette M; Lina B; Morfin F; Ferraris O
J Clin Virol; 2008 Jan; 41(1):25-8. PubMed ID: 18055253
[TBL] [Abstract][Full Text] [Related]
32. Mixed influenza A and B infections complicate the detection of influenza viruses with altered sensitivities to neuraminidase inhibitors.
Mohr PG; Geyer H; McKimm-Breschkin JL
Antiviral Res; 2011 Jul; 91(1):20-2. PubMed ID: 21549758
[TBL] [Abstract][Full Text] [Related]
33. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors.
Gubareva LV
Virus Res; 2004 Jul; 103(1-2):199-203. PubMed ID: 15163510
[TBL] [Abstract][Full Text] [Related]
34. [Criteria for the use of anti-influenza agents].
Kashiwagi S
Nihon Rinsho; 2003 Nov; 61(11):1963-6. PubMed ID: 14619439
[TBL] [Abstract][Full Text] [Related]
35. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en.
Staschke KA; Colacino JM; Baxter AJ; Air GM; Bansal A; Hornback WJ; Munroe JE; Laver WG
Virology; 1995 Dec; 214(2):642-6. PubMed ID: 8553569
[TBL] [Abstract][Full Text] [Related]
36. Neuraminidase inhibitors slightly beneficial for shortening flu symptoms.
Phillips TG
J Fam Pract; 2003 Oct; 52(10):747-8. PubMed ID: 14529590
[No Abstract] [Full Text] [Related]
37. Neuraminidase inhibitors in the management of influenza--experience of an outpatient practice.
Vogel GE
Med Microbiol Immunol; 2002 Dec; 191(3-4):161-3. PubMed ID: 12458352
[TBL] [Abstract][Full Text] [Related]
38. Zanamivir: from drug design to the clinic.
Elliott M
Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1885-93. PubMed ID: 11779388
[TBL] [Abstract][Full Text] [Related]
39. Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza.
Magano J
Chem Rev; 2009 Sep; 109(9):4398-438. PubMed ID: 19537777
[No Abstract] [Full Text] [Related]
40. Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.
Watson KG; Cameron R; Fenton RJ; Gower D; Hamilton S; Jin B; Krippner GY; Luttick A; McConnell D; MacDonald SJ; Mason AM; Nguyen V; Tucker SP; Wu WY
Bioorg Med Chem Lett; 2004 Mar; 14(6):1589-92. PubMed ID: 15006410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
